Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 33

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 33
---
 Aptorum’s and DiamiR’s visions are aligned regarding                                                                                          
 combining therapeutic programs with accurate and minimally invasive biomarker panels for better patient outcomes; success in drug development 
 is partly dependent on having the tools and technologies to recruit the “right” patient into clinical studies and to monitor                  
 drug response in study participants; DiamiR can help Aptorum develop and use a number of different diagnostic platforms to achieve this       
 goal; DiamiR’s robust IP portfolio will allow this work to remain proprietary and gives the Combined Company an edge in the market            
 place for such services;                                                                                                                      |

| ● | DiamiR’s patent-protected platform technology has shown                                                                              
 to be effective in detecting and differentiating neurodegenerative diseases, cancer, and inflammatory diseases; we believe there are 
 synergies with Aptorum’s programs, in particular SACT-1 drug repurposing program;                                                    |

| ● | Aptorum and its executives have strong background in clinical                            
 services; DiamiR pursues dual business model of clinical testing and biopharma services; |

| ● | DiamiR’s CLIA-certified, CAP-accredited laboratory is                                                                                    
 staffed with experienced assay development executives and staff with years of experience in developing molecular and biomarker testing   
 solutions. Prior to its acquisition by DiamiR, the laboratory and its team validated and launched the first commercially available miRNA 
 clinical test in oncology (thyroid cancer) and will apply their know-how to help Aptorum in its clinical development programs;           |

| ● | The combination with Aptorum Group will allow DiamiR to grow                         
 as part of a global company with broader network of experts and key opinion leaders; |

| ● | Business combination with a publicly listed company is expected                                                                      
 to provide DiamiR with access to additional resources, including capital, to advance its product candidates for brain health, cancer 
 and inflammatory diseases and to create value to shareholders;                                                                       |

| ● | DiamiR’s lead program is focused on detecting, monitoring,                                                                       
 and predicting risk of progression of brain health indications, such as mild cognitive impairment and Alzheimer’s disease; there 
 is a huge need in these testing solutions and a public company platform is better suited for this objective.                     |

After giving consideration to these and other factors (including such factors as mentioned above for Aptorum’s reasoning for entering the merger), DiamiR’s board of directors approved the Merger, which the DiamiR board of directors believes better positions DiamiR for long-term